Advanced search
Publication Cover
Hematology Volume 29, 2024 - Issue 1
Submit an article Journal homepage
698
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan

Yoko Edahiroa Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;b Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;c Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8386-1871View further author information
ORCID Icon,
Tomonori Ochiaia Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;b Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;c Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Tokyo, JapanView further author information
,
Yoshinori Hashimotoa Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;d Department of Hematology, Tottori Prefectural Central Hospital, Tottori, JapanView further author information
,
Michiko Ichiie Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, JapanView further author information
,
Takeshi Okatanif Division of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, JapanView further author information
,
Hiromi Omurad Department of Hematology, Tottori Prefectural Central Hospital, Tottori, JapanView further author information
,
Kei Nakajimag Department of Hematology/Oncology, University of Yamanashi, Yamanashi, JapanView further author information
,
Makoto Sasakib Department of Hematology, Juntendo University School of Medicine, Tokyo, JapanView further author information
,
Jun Andob Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;h Division of Cell Therapy & Blood Transfusion Medicine, Juntendo University School of Medicine, Tokyo, JapanView further author information
,
Tomoiku Takakub Department of Hematology, Juntendo University School of Medicine, Tokyo, JapanView further author information
,
Michiaki Koikei Department of Hematology, Juntendo University Shizuoka Hospital, Shizuoka, JapanView further author information
,
Koh Izumiyamaj Blood Disorders Center, Aiiku Hospital, Hokkaido, JapanView further author information
,
Junji Hiragak Department of Hematology, Toyota Kosei Hospital, Aichi, JapanView further author information
,
Tomofumi Yanol Internal Medicine Department, Okayama Rosai Hospital, Okayama, JapanView further author information
,
Kensuke Usukim Department of Hematology, NTT Medical Center Tokyo, Tokyo, JapanView further author information
,
Eiichi Ohtsukan Department of Hematology, Oita Prefectural Hospital, Oita, JapanView further author information
,
Kenji Yokoyamao Department of Hematology/Oncology, Tokai University Hachioji Hospital, Tokyo, JapanView further author information
,
Tatsuo Oyakep Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, JapanView further author information
,
Naoki Takahashiq Department of Hematopoietic Tumor, International Medical Center, Saitama Medical University, Saitama, JapanView further author information
,
Tetsuya Nishidar Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, JapanView further author information
,
Takafumi Nakaos Department of Hematology, Osaka City General Hospital, Osaka, JapanView further author information
,
Yasutaka Fukudat Department of Hematology, Juntendo University Nerima Hospital, Tokyo, JapanView further author information
,
Takashi Akasakau Department of Hematology, Tenri Hospital, Nara, JapanView further author information
,
Atsuko Mugitaniv Department of Hematology, Seichokai Fuchu Hospital, Osaka, JapanView further author information
,
Miki Andob Department of Hematology, Juntendo University School of Medicine, Tokyo, JapanView further author information
&
Norio Komatsua Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan;b Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;c Laboratory for the Development of Therapies against MPN, Juntendo University Graduate School of Medicine, Tokyo, Japan;w PharmaEssentia Japan KK, Tokyo, JapanView further author information
 show all
Article: 2340149 | Received 07 Dec 2023, Accepted 02 Apr 2024, Published online: 16 Apr 2024

References

  • Marchetti M, Ghirardi A, Masciulli A, et al. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2020;95:295–301. doi:10.1002/ajh.25700
  • Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96:454–458. doi:10.3324/haematol.2010.033779
  • Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18:2068–2073. doi:10.1158/1055-9965.EPI-09-0353
  • Brunner AM, Hobbs G, Jalbut MM, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma. 2016;57:1197–1200.
  • Palandri F, Derenzini E, Ottaviani E, et al. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0–1) diffuse large B-cell lymphoma. Leuk Lymphoma. 2009;50:1824–1824. doi:10.3109/10428190903216796
  • Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152–156. doi:10.1111/ejh.12410
  • Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32:2203–2210. doi:10.1038/s41375-018-0027-y
  • Masarova L, Newberry KJ, Pierce SA, et al. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015;39:822–827. doi:10.1016/j.leukres.2015.05.002
  • Sakata-Yanagimoto M, Yokoyama Y, Muto H, et al. A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms. Ann Hematol. 2016;95:829–830. doi:10.1007/s00277-016-2612-3
  • Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33:1996–2005. doi:10.1038/s41375-019-0487-8
  • Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132:694–706.
  • Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019;133:2348–2351. doi:10.1182/blood-2019-01-897637
  • Hashimoto Y, Ito T, Gotoh A, et al. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. Int J Hematol. 2022;115:208–221. doi:10.1007/s12185-021-03253-0
  • Edahiro Y, Ito T, Gotoh A et al. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. Int J Hematol. 2022;116:696–711.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.